BB-401
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Squamous Cell Carcinoma
Conditions
Head and Neck Squamous Cell Carcinoma
Trial Timeline
Mar 15, 2018 → Apr 6, 2020
NCT ID
NCT03433027About BB-401
BB-401 is a phase 2 stage product being developed by Benitec Biopharma for Head and Neck Squamous Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03433027. Target conditions include Head and Neck Squamous Cell Carcinoma.
What happened to similar drugs?
11 of 20 similar drugs in Head and Neck Squamous Cell Carcinoma were approved
Approved (11) Terminated (0) Active (9)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03433027 | Phase 2 | Completed |
Competing Products
20 competing products in Head and Neck Squamous Cell Carcinoma